Abstract Toll-like receptors (TLRs) are pattern recognition receptors mainly expressed by cells of the immune system but also by epithelial tumor cells. Little is known about expression patterns of TLR genes in breast tumors, and their clinical significance is unclear. The aim of our study was to investigate expression of TLRs pathway components in pre-invasive breast lesions and invasive breast carcinomas (IBCs). We used RT-PCR assays to quantify mRNA levels of the 10 TLR genes and genes involved in TLR pathways in 350 breast tumors from patients with known clinical/pathological status and long-term outcome. Sets of 158 breast samples were also analyzed by immunochemistry including; 40 early noninvasive breast lesions, 38 IBCs and 80 triple negative carcinomas subtype (TNCs). We identified TLR9 as the major TLR gene family member upregulated in breast tumors and more particularly in TNCs. Immunohistochemical studies demonstrated that TLR9 protein was expressed in tumor epithelial and stromal cells of the TLR9 mRNA-overexpressing tumors. TLR9 overexpression appears very early during breast carcinogenesis. High TLR9 levels were associated with favorable outcome in the TNC sub-group. TLR9 overexpression was associated with alterations of down-stream components of the TLR9 signaling pathway, epithelio-mesenchymal transition (EMT) induction and EGFR pathway deregulation. TNCs with TLR9 overexpression were significantly correlated with development of a fibrous and inflammatory microenvironment with variable status of nuclear phosphoSTAT3. Our results suggest that TLR9 could play a role in TNC carcinogenesis and could be useful as predictive biomarker and therapeutic target.
Introduction
Invasive breast carcinomas (IBCs) are highly heterogeneous tumors, and triple negative subtype (TNC) remains a major cause of death in women. Thus, identification of new prognostic factors is crucial to improve the classical histoprognostic classification of breast tumors. Among breast carcinomas, TNCs represent 10 to 15 % of IBCs and are characterized by an aggressive clinical course and a poor prognosis, owing partly to the lack of targeted therapies [1] [2] [3] .
Cancer microenvironment is a complex network driving cancer cells fate from invasion to intravasation and metastasis. Reciprocal interactions between neoplastic cells and their microenvironment are pivotal events in carcinogenesis and tumor progression [4] . IBCs and particularly TNCs are usually characterized by establishment of a predominant stromal program with central necrotic/fibrotic areas, and a huge peripheral inflammatory infiltrate [5] . Inflammation has recently emerged as a non-mutational driver of carcinogenesis and is now considered as a new hallmark of cancer. Recent data have underlined the crucial role of the inflammatory microenvironment in IBCs carcinogenesis and particularly in the TNC subtype [6, 7] . Inflammation is usually induced by activation of innate immune receptors such as Toll-like receptors (TLRs) and cytokines receptors.
TLRs belong to the evolutionarily conserved family of Pattern Recognition Receptors (PRR). Ten functional TLRs have been identified in humans and 13 in mice. TLRs function as receptors of the innate immunity system for detection and response to pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPS), which include a large spectrum of microbial components and endogenous molecules released by injured tissue [8, 9] . Cell surface TLRs (TLR1, TLR2, TLR4, TLR5, TLR6 and TLR10) recognize microbial membrane lipids, whereas endosomal TLRs (TLR3, TLR7, TLR8, TLR9) recognize pathogen and hostderived nucleotides, including unmethylated CpG motifs of DNA and double or single-stranded RNA [10] . TLRs play a crucial role of molecular sensors, essentially by bridging innate and adaptive immunity. Activation of TLRs results in production of type I interferon (IFNs), cytokines and chemokines that finally initiate inflammation, recruit immune cells and activate adaptive immunity [11, 12] . TLRs are preferentially expressed by immune cells but also by normal and cancer epithelial cells of various origins [13, 14] . In cancer, tumor cells death results in release of numerous proteic or nucleic DAMPs that activate TLRs of both immune/stromal cells and epithelial cancer cells. Increasing evidence has indicated that TLRs expression by cancer cells and immune cells seems to be twofold by either promoting or inhibiting tumor progression [6, 15, 16] .
The aim of this study is to investigate TLRs expression in IBCs particularly in TNC subtype and their relationship with clinico-biological data and prognosis.
Materials and Methods

Patients and Samples
Samples of 350 unilateral invasive primary breast tumors excised from women managed at Curie Institute, Saint-Cloud, France from 1978 to 2008 were analyzed. The samples were immediately stored in liquid nitrogen until RNA extraction. A tumor sample was considered suitable for our study if the proportion of tumor cells exceeded 70 %. All patients (mean age 61.7 years, range 31-91 years) met the following criteria: primary unilateral non metastatic breast carcinoma for which complete clinical, histological and biological data were available; no radiotherapy or chemotherapy before surgery; and full follow-up at René Huguenin Hospital.
Treatment consisted in modified radical mastectomy in 221 cases (63.1 %) and breast-conserving surgery plus locoregional radiotherapy in 129 cases (36.9 %). The patients had a physical examination and routine chest radiotherapy every 3 months for 2 years, then annually. Mammograms were performed annually. Adjuvant therapy was administered to 292 patients, consisting in chemotherapy alone (n = 76), hormone therapy alone (n = 150) and both treatments (n = 66). The histological subtype and the number of positive axillary lymph nodes were evaluated at the time of surgery. IBCs were assessed according to Scarff Bloom Richardson's (SBR) histoprognosis grading system. Hormone receptor (HR) (i.e. estrogen receptor (ER) and progesterone receptor (PR) and human epidermal growth factor receptor 2 (ERBB2) statuses were determined at the protein level by using biochemical methods (dextran-coated charcoal method, enzyme immunoassay or immunohistochemistry) and confirmed by real-time quantitative RT-PCR assays [17, 18] . The population was divided into four groups according to HR (ER and PR) and ERBB2 status, as follows: two luminal subtypes [HR+/ERBB2+ (n = 45)] and [HR+/ERBB2-(n = 195)]; an ERBB2+ subtype [HR-/ERBB2+ (n = 46)] and a triplenegative subtype [HR-/ERBB2-(n = 64)]. With a median follow-up of 8.9 years (range 6 months to 29 years), 143 patients presented metastases. 10 specimens of adjacent normal breast tissue from breast cancer patients and normal breast tissue from women undergoing cosmetic breast surgery were used as sources of normal RNA. Another series of 80 TNCs was used for prognostic analysis. An additional series of 50 breast tissues; 10 normal breast tissues and 40 early noninvasive breast lesions, including atypical columnar metaplasia (ACM; n = 10), atypical ductal hyperplasia (ADH; n = 10) and ductal carcinoma in situ (DCIS; n = 20), were selected for protein level analysis through immunohistochemistry. Finally, we analyzed 39 breast tumors xenografts. We previously showed that these xenografts analyzed in the present study reproduced the marked heterogeneity of human tumors and generally very closely resemble the patient's tumor in terms of histopathologic and molecular features [19] [20] [21] . The experimental protocol and animal housing were in accordance with institutional guidelines of the French Ethical Committee (Agreement B75-05-18, France).
RNA Extraction
Total RNA was extracted from breast tissue samples by using acid-phenol guanidium as previously described. RNA quality was determined by electrophoresis through agarose gels, staining with ethidium bromide and visualization of the 18S and 28S RNA bands under ultraviolet light.
Real-Time RT-PCR
Quantitative values were obtained from the cycle number (Ct value) at which the increase in the fluorescence signal associated with exponential growth of PCR products started to be detected by the laser detector of the ABI Prism 7900 sequence detection system (Perkin-Elmer Applied Biosystems, Foster City, CA), using PE biosystems analysis software according to the manufacturer's manuals. The precise amount of total RNA added to each reaction mix (based on optical density) and its quality (i.e., lack of extensive degradation) were both difficult to assess. Therefore, transcripts of the TBP gene (Genbank accession NM_003194) encoding the TATA box-binding protein (a component of the DNA-binding protein complex TFIID) were also quantified as an endogenous RNA control. Each sample was normalized on the basis of its TBP content. TBP was selected as an endogenous control due to the moderate prevalence of its transcripts and the absence of known TBP retropseudogenes (retropseudogenes lead to coamplification of contaminating genomic DNA and thus interfere with RT-PCR, despite the use of primers in separate exons) [17] . Results, expressed as N-fold differences in target gene expression relative to the TBP gene and termed BNtarget^, were determined as Ntarget = 2 ΔCtsample , where the ΔCt value of the sample was determined by subtracting the average Ct value of target gene from the average Ct value of TBP gene. The target gene values of the breast tumor samples were subsequently normalized such that the median of the target gene values for the 10 normal breast tissues was 1. The primers for TBP, the 10 TLRs and others genes were chosen with the assistance of the Oligo 6.0 program (National Biosciences, Plymouth, MN). dbEST and nr databases were scanned to confirm the total gene specificity of the nucleotide sequences chosen for the primers and the absence of single nucleotide polymorphisms. The primer pairs for each TLR isoform genes were selected to be unique when compared with the sequences of the others TLR genes. To avoid amplification of contaminating genomic DNA, one of the two primers was placed at the junction between two exons or on two different exons. Agarose gel electrophoresis was used to verify the specificity of PCR amplicons. The conditions of cDNA synthesis and PCR were as previously described [22] . To quantify by real-time quantitative RT-PCR the specific human TLR9 mRNA levels in the total RNAs extracted from the 39 human breast xenografts, we used a human-specific TLR9 RT-PCR assay. The human Hs-TLR9 primer pair was selected to be unique when compared to the sequence of the murine TLR9 mRNA, whereas the Total-TBP primer pair was selected to amplify both the mouse and the human TBP genes that used as endogenous RNA control. The NHs-TLR9 values of the breast tumor xenograft samples were subsequently normalized such that the value for the Bbasal mRNA level^(smallest amount of Hs-TLR9 mRNA quantifiable, Ct = 35) was 1. Hs-TLR9 mRNA levels that were totally absence or very low (Ct > 35; detectable but not reliable quantifiable) in breast tumor, xenograft samples were scored B0^(no expression).
Immunohistochemistry
Paraffin-embedded tissue blocks, obtained at the time of the initial diagnosis were retrieved from the archives of the Department of Biopathology, René Huguenin Hospital. Sections of 3 μm in thickness were cut with a microtome from the paraffin-embedded tissue blocks of normal breast tissue, pre-invasive lesions and IBCs. Tissue sections were dewaxed and rehydrated through a series of xylene and ethanol washes. Briefly, primary antibodies (abs) against pan-cytokeratin AE1/ AE3, vimentin, smooth muscle actin, E-cadherin, ZEB2 and EGFR were used. Immunostaining was processed by using a Dako automated device except for TLR9 assay that was performed with a primary monoclonal antibody (Imgenex, Cambridge, UK) at a dilution of 1/50 associated with an antibody diluent (Invitogen 00-3218) and incubated overnight at 4°C. The specificity of the TLR9 abs was confirmed via the same protocol on paraffin-embedded human tissue sections containing lymphocytes. In addition, we realized positive and negative TRL9 test controls on normal breast tissue -terminal duct lobular unit (TDLU) (Supplemental Figure 1 ). For each case of TRL9 immunostaining, two sections of paraffin-embedded breast tissue of IBCs and TNCs were performed; one section in the center of the tumor and second section including tumor microenvironment and invasion margins. Then, TRL9 immunostaining slides were anonymized and blinded for the interpretation of immunostaining score. A semi quantitative intensity score (H score) was used for TLR9 (score 0: negative staining, score 1: weak cytoplasmic staining, score 2: moderate cytoplasmic staining, score 3: strong cytoplasmic staining in most of tumor cells, score 4: strong cytoplasmic and sub membranous staining in almost all tumor cells). Slides were scored by three pathologists in two working groups. The pathologists did not know neither hormone receptors nor HER2 status before slides interpretation. TLR9 normal breast tissue expression levels were observed with H score between > 1 and < 2. TLR9 underexpression was defined with H score between 0 and 1 and TLR9 overexpression with a H score between 2 and 4.
For anti-STAT3 antibody (phosphoS727, abcam, ab32143, pH6, 1/200) and anti-STAT3 antibody (phosphor Tyr705, Cell Signaling, D3A7, pH9, 1/50), only tumors that showed more than 10 % nuclear staining in cancer cells and stromal/immune cells were considered as positive.
We performed immunohistochemical study of the tumor microenvironment by using TLR9 immunostaining in stromal cancer associated fibroblasts (CAFs) and mononuclear inflammatory cells (MICs). Then, we used several abs to distinguish different subpopulations of MICs (CD3, CD20, CD4, FoxP3, CD8/ CD45RO and CD68), with a semi quantitative score (score 0: negative, score 1: <5 %, score 2: 5 to 20 %, score 3: > 20 %). We also evaluated the density of microvessels by using a CD31 abs with the same semi quantitative score. All immunostaining was processed using a Dako abs (Dako, Glostrup, Denmark), except of CD8 and CD4 (Novocastra, Newcastle, UK).
Statistical Analysis
The distributions of target mRNA or protein levels were characterized by their median values and ranges. Relationships between mRNA levels of the different target genes, and between mRNA levels and clinical parameters, were identified using nonparametric tests, namely the chi-square test (relation between two qualitative parameters), the Mann-Whitney U test (relation between one qualitative parameter and one quantitative parameter) and the Spearman rank correlation test (relation between two quantitative parameters). Differences were considered significant at confidence levels greater than 95 % (P < 0.05). In order to evaluate the efficacy of a molecular marker (TLR9 level) in two populations (metastatic versus non metastatic patients) in the absence of an arbitrary cut-off value, data were summarized in an ROC (receiver operating characteristic) curve [23] . The AUC (area under curve) was calculated as a single measure for discriminate efficacy. Metastasis-free survival (MFS) was determined as the interval between initial diagnosis and detection of the first metastasis. Survival distributions were estimated by the Kaplan-Meier method, and the significance of differences between survival rates were ascertained with the log-rank test.
Results
Endosomal TLR8 and TLR9 are Overexpressed in IBCs
We measured mRNA levels of the 10 TLRs isoforms in a first series of 84 patients (21 HR+/ERBB2+, 21 HR+/ERBB2-, 21 HR-/ERBB2+ and 21 HR-/ERBB2-) with unilateral invasive breast tumors, and in 10 normal breast tissues by using quantitative RT-PCR assays (Supplemental table 1). For the 10 TLR genes, the mRNA values of the breast cancer samples were normalized such that the median of the 10 normal breast tissue mRNA values was 1. To determine the cut-off point for altered TLR isoforms expression in breast cancer tissues, the NTLR value, calculated as described in Materials and Methods, was determined for 10 normal breast RNA samples. As these values were consistently between 0.02 (TLR9) and 2.76 (TLR6), values of 3 or more were considered to represent overexpression of these 10 genes in tumor RNA samples. We previously used the same approach to determine cut-off points for tumor gene overexpression [24, 25] . Only TLR9 gene (and to a lesser extent TLR8) exhibited marked overexpression in breast tumors, mainly in the HR-/ERBB-/TNC subgroup (TLR8: med 3.15, min 0.38, max 11.33; TLR9: med 6.07, min 0.54, max: 52.05). In the present study, the overexpressions of TLR8 ( P = 0.047) and TL R9 (P = 0.00098) in TNC subgroup were statistically significant ( Table 1) . Consequently, we further studied TLR9 (and stopped studying the 9 others TLR genes) in the subsequent analyzes.
TLR9 Protein is Overexpressed in Breast Cancer Cells
TLR9 mRNA Expression is Correlated With Amount of the Protein in IBCs
IHC assay performed from a subgroup of 38 breast tumors belonging to the series of 84 tumors tested by quantitative RT-PCR, confirmed TLR9 protein localization in breast epithelial cancer cells. Carcinoma cells exhibited a diffuse cytoplasmic TLR9 staining with various intensity and sub membranous (endolysosomal localization) accentuation in some cases (Fig. 1) . Stromal cells, including immune cells, endothelial cells, fibroblasts and adipocytes were used as internal positive controls. TLR9 overexpression (Supplemental Table 2) was observed at protein level in our first series of 38 IBCs (n = 8/38; 21 %), including 13 TNCs (n = 5/13; 38.5 %). TLR9 protein overexpression in the TNC subgroup was confirmed in a larger series of 80 TNCs (n = 32/80; 40 %). A statistically significant correlation was identified (P = 0.0086; Mann-Whitney U test) between TLR9 mRNA and protein expression levels, suggesting that TLR9 deregulation is mainly transcriptional in breast tumors.
TRL-9 Protein is Expressed in pre-Invasive Breast Lesions
To determine whether TLR9 protein showing marked upregulation in invasive breast tumors is also expressed at an early step of breast carcinogenesis, we analyzed TLR9 expression by immunohistochemistry in a series of 10 normal breast tissues and 40 pre-invasive neoplastic lesions. A discrete physiological sub-apical and cytoplasmic immunostaining was inconstantly observed in some luminal cells of normal breast tissue (Supplemental Figure 2A) , and a diffuse TLR9 cytoplasmic immunoreactivity was observed in pre-invasive breast lesions from the initial stage of atypical columnar metaplasia (IHC score 1; Supplemental Figure 2B ) with a stronger staining in atypical ductal hyperplasia (IHC score 2; Supplemental Figure 2C ) and ductal carcinoma in situ (IHC score 3; Supplemental Figure 2D ).
TLR9 mRNA Levels of Expression are Observed in Human Breast Tumor Xenografts
To confirm TLR9 expression in the cancer epithelial cells, we specifically quantified the human TLR9 transcript in a series of 39 human breast tumors xenografted in mice. We used this species-specific PCR array to distinguish human/ epithelial TLR9 expression from murine/stromal TLR9 expression. We observed marked human TLR9 transcripts (Ct < 35) in 92.3 % (n = 36/39) of the human breast tumor xenografts. The NHs-TLR9 values ranged from 1 to 60.4 (median = 7.2).
TLR9 mRNA Expression is Correlated With Classical Clinicopathological Prognosis Factors and Metastasis-Free Survival
In order to determine the prognosis significance of expression pattern of TLR9 in human breast tumors, we analyzed TLR9 mRNA levels in a large series of 350 primary breast tumors from patients with known clinical/pathological status and long-term outcome (Table 2) . Among the 350 breast tumor RNA samples tested, 50 IBCs (14.3 %) showed TLR9 mRNA overexpression (NTLR9 from 3.02 to 49.9). We sought links between TLR9 mRNA level status and standard clinicopathological and biological factors in breast cancer. Significant positive associations were observed between the tumor group showing TLR9 overexpression and histopathological grade III (P = 0.000083), estrogen receptor negative (P = 0.00000067), progesterone receptor negative (P = 0.00056) and molecular subtypes (P = 0.000012). Among the 64 TNC (RH-/ERBB2-) samples tested, 19 tumors (29.7 %) showed TLR9 mRNA overexpression, compared to the total breast tumor population (14.3 %).
Recent literature data suggested that TLR9 is implicated in induction of EMT mainly through NF-kB activation [6] . EMT plays an important role in breast cancer metastasis, especially in the TNC subtype. We hypothesized that TLR9 overexpression could promote EMT in TNCs. We analyzed 9 major candidate transcripts involved in EMT (Supplemental Table 3 ) in the series of 71 TNCs (Supplemental Table 4 ). We observed a significant positive association between TLR9 expression and ZEB2, and a trend towards significance with SNAIL, TWIST1 and VIM (only significantly using the Spearman rank correlation test). Significant positive correlations in the total population of 350 breast tumor RNAs were confirmed between TLR9 and TWIST1 (r = +0,167; P = 0.002) and VIM (r = +0,203; P = 0.0002). It is noteworthy that no correlation was observed between TLR9 and CDH1/E-cadherin (r = −0,010; Table 5 ).
Interactions between TLR9 and EGFR pathways were recently identified in colorectal cancer [26] . We previously observed by RT-PCR and IHC only a low percentage (11 %) of EGFR overexpression in the TNC subgroup and mainly EGFR under-expressions in the 3 other subgroups [27] . In the present study, we observed a positive statistical correlation between TLR9 and EGFR mRNA levels (r = 0,437; P < 10 To further investigate whether TLR9 mRNA expression could be of prognosis relevance, the log-rank test was used to identify link between MFS (metastasis-free survival) and TLR9 mRNA expression. Firstly, the relationship between RFS and TLR9 overexpression status was analyzed using the Log-rank test at the threshold of 3. Results showed that MFS was not significantly influenced by TLR9 overexpression status (P = 0.30) (data not shown). Area under the curve analyzes were performed to identify the cut-point allowing to divide the cohort into relevant TLR9 expression subgroups. We therefore compared tumors with low TLR9 expression (NTLR9 ≤ 0.59; n = 138; 39.4 %), with those with moderate and high TLR9 expression (NTLR9 > 0.59; n = 212; 60.6 %). High TLR9 mRNA levels showed a trend towards significance association with better MFS (P = 0.05) (Fig. 2a) . At the protein level, we could identify in our series of 80 TNCs a statistically significant correlation between high TLR9 protein levels with better MFS (P = 0.0000011) (Fig. 2b) . As we observed TLR9 overexpression more frequently associated with histopathological grade III and estrogen receptor negative, but associated with favorable outcome in the total population (Table 3) , we tested relationship between TLR9 expression and MFS in these three tumor subgroups of poor prognostic. High TLR9 mRNA levels of expression showed significance association with favorable MFS in histopathological grade III (P = 0.043) and estrogen receptor negative (P = 0.007) (data not shown).
TLR9 Signaling Pathways are Activated in TLR9-Overexpressed TNCs and Induce Overexpression of NF-kB, Cytokines and Chemokines
To explore the possible activation of the TLR9 signaling pathways in the TLR9-overexpressed breast tumors, we tested relationship between expression of 25 genes involved in the MyD88 and TICAM1/TRIF pathways in 36 low TLR9-expressing TNCs and 35 high TLR9-expressing TNCs. We selected a homogenous population of tumors (only TNCs), as it represents the breast cancer subtype with the highest proportion of TLR9-overexpressed tumors. We selected 25 major candidate genes involved in the TLR9 downstream/ interconnected signaling pathways from literature's data: (i) endosomal TLR7, 8 and 9 (n = 3), (ii) molecular adaptors MYD88 and TICAM1/TRIF (n = 2), (iii) downstream TICAM1/TRIF and MyD88 pathways (n = 4), (iv) transcriptional factors IRF (n = 2) and NFkB (n = 8) and (v) inflammatory cytokines and chemokines (n = 6). By using both the Mann-Whitney U test (relation between one qualitative parameter and one quantitative parameter) and the Spearman rank correlation test (relation between two quantitative parameters), we found a significant positive association between (i) TLR9 expression and (ii) TLR7, TLR8 (Toll-like receptors), MYD88 (molecular adaptors), IKBKE, IRAK1, IRAK3 (downstream pathways), IRF7, IRF3 (IRF transcription factor), RELB, NFKB2, NFKB1, NFKIB, NFKBIA, REL (NFkB complex) and TNF, IFNγ, IL1β and IL6 (inflammatory cytokines and chemokines) (Supplemental Table 5 tumor RNAs were identified between TLR9 and IKBKE (r = + 0,401; P < 10 −7 ), NFKB1 (r = +0.296; P = 0.0000002) and TNF (r = +0.582; P < 10
−7
).
TLR9 is Also Overexpressed by Immune/Inflammatory and Stromal Cells of the Tumor Microenvironment
Because TLR9 signaling pathways induce overexpression of cytokines and chemokines, we analyzed different subtypes of stromal cells in our series of 80 TNCs (Supplemental Table 6 ). We performed TLR9, CD4, CD8, FoxP3, CD45RO and CD31 immunostaining of cancer-associated fibroblasts (CAFs), mononuclear inflammatory cells (MICs), cytotoxic and memory T lymphocytes and endothelial cells. We could observe in TNCs significant positive correlations between cancer cells overexpressing TLR9 and fibrous (P = 1.2×10
) and inflammatory stromal profiles (P < 10
) with accumulation of CAFs (P = 7×10 ).
Immunohistochemical analysis of TLR9 expression in epithelial cancer cells and stromal cells suggests the existence of phenotypic profiles with prognosis significance, depending on TLR9 expression pattern by cancer cells and immune/stromal cells, presence of an inflammatory/immune infiltrate and microvessel density. Three subtypes could be identified (Supplemental Figure 3) : (i) a first subtype (n = 32/80; 40 %) associating high TLR9 expression by cancer cells, a desmoplastic and hypercellular stroma, numerous CAFs and MICs overexpressing TLR9 (score 3), and a high microvessel density (score 3), (ii) a second subtype (n = 27/80; 33 %) associating low TLR9 expression by cancer cells, a predominantly edematous stroma, rare CAFs and MICs overexpressing TLR9 (score 1) and a low microvessel density (score 1), and (iii) a third subtype (n = 21/80; 27 %) associating low TLR9 expression by cancer cells, a predominantly fibrotic and hypocellular stroma, moderate number of CAFs and MICs overexpressing TLR9 (score 2) and a moderate microvessel density (score 2).
We found that TNCs with overexpressed TLR9 protein were associated with a better MFS (P = 0.0000011) and that TNCs with an inflammatory microenvironment with numerous CAFs, MICs and CD8 lymphocytes were associated with a better prognosis (respectively P = 0.000012, P = 0.000013, P = 0.0000042 and P = 0.00000076). During cancer progression, development and maintain of cancer-associated inflammation is provided by a chemokine inducer initiated by simultaneous activation of NF-kB and signal transducer and activator of transcription 3 (STAT3). In order to explore these 2 co-activators located both in stromal/ immune cells of the tumor microenvironment and in epithelial cancer cells, we finally performed phosphoSTAT3 immunostaining (Tyr705 and Ser727) in our series of 80 TNCs. We could observe that in TNCs with TLR9 overexpression (n = 32/80; 40 %), nuclear phosphoSTAT3 (Tyr705) was observed in 81.2 % (n = 26/32) of epithelial cancer cells (Supplemental Figure 4) as compared to nuclear phosphoSTAT3 (Tyr705) immunostaining of cancer cells belonging to the 48 normal or low TLR9 expressed TNCs (n = 15/48; 31.2 %; P = 0.000012). Conversely, by using phosphoSTAT3 Ab (Ser727), we showed that in TNCs with TLR9 overexpression, nuclear positivity was observed in 21,9 % (n = 7/32) of epithelial cancer cells as compared to nuclear immunostaining of cancer cells belonging to the normal or low TLR9 expressed TNCs (n = 32/48; 66.7 %)(P = 0.000086). PhosphoSTAT3 (Tyr705) and phosphoSTAT3 (Ser727) were also variably expressed by immune and nonimmune stromal cells.
Discussion
TLRs are actually considered as major actors implicated in chronic inflammatory-driven carcinogenesis [28, 29] . In the present study, we hypothesized that a functional TLR pathway may exist in IBCs, particularly in the TNC subtype and be activated by both epithelial cancer cells and stromal cells. We analyzed expression levels of TLRs and downstream and interconnected signaling pathways molecules at the mRNA level by real time quantitative RT-PCR and at the protein level by immunohistochemistry. Among the 10 TLRs analyzed, TLR9 and to a lesser extent TLR8 endosomal TLRs were overexpressed in our series of IBCs. TLR9 mRNA overexpression was observed in 14.3 % (n = 50/350) of breast tumors but interestingly in 29.7 % (n = 19/64) of the TNC subtype. By using IHC, TLR9 was not only expressed by the neoplastic epithelial population but also by several subtypes of stromal and immune/inflammatory cells belonging to the tumor microenvironment. Epithelial cancer cells expressed TLR9 with varying frequency (0 to 100 %), intensity levels (score 0 to 4) and topography, including cytoplasmic/endosomal and rarely nuclear or sub membranous localization. Significant statistical positive correlation was observed between TLR9 mRNA and protein expression levels (P = 0.0086). We also confirmed TLR9 expression in cancer epithelial cells by quantifying specifically the human TLR9 transcript in a large series of 39 human malignant breast tumours xenografted in mice. Taken together, our results showed that TLR9 transcripts are translated into TLR9 protein in tumor epithelial cells, with a strong correlation between TLR9 mRNA overexpression and TLR9 protein abundance, suggesting regulation at transcriptional level. Moreover, TLR9 overexpression in pre-invasive breast lesions is indicative that TLRs may play a pivotal role at early stages of breast carcinogenesis.
EMT was recently identified as a crucial morphomolecular process in cancer progression. NFkB family of transcription factors plays pivotal roles in both promoting and maintaining an invasive phenotype mainly by controlling master regulators of EMT and by repressing epithelial phenotype. In our series, significant positive correlations were observed between TLR9 and ZEB2, TWIST1 and VIM. Ultimately, as an interconnection was recently identified between TLR9 and EGFR pathways, we also explored EGFR at mRNA level and identified a We further investigated whether TLR9 overexpression by cancer epithelial cells was associated with TLR signaling pathway overexpression/activation [30] . By using real time quantitative RT-PCR in the TNC subgroup of IBCs, we confirmed that TNCs overexpressing TLR9 were characterized by activation of numerous genes implicated in TLR9 downstream signal transduction pathways: adaptors (MYD88), intracellular multimolecular mediators (IKBKE, IRAK1, IRAK3) and transcription factors (IRF7, IRF3, NFkB complex). In accordance with the literature, we did not observe overexpression of TICAM/TRIF and TRAF6 usually activated after dimerization of endosomal TLR3 and cell membrane TLR1 to TLR6 and TLR10 [31] .
Functional and activated TLRs play a pivotal role in promoting reciprocal interactions between cancer epithelial cells and their microenvironment during tumor progression. Cancer epithelial and stromal/immune cells overexpressing TLRs release numerous cytokines, chemokines, metalloproteases and integrins [32] [33] [34] . This resulting profile is associated with immune tolerance, tumor progression and promotion of angiogenesis. By using RT-PCR in our series of TNCs, we could observe overexpression of pro-inflammatory cytokines, including TNF, IFNγ, IL1β and IL6, in accordance with activation and nuclear translocation of transcription factors NF-kB, IRF7 and IRF3. These data were consistent with morphological characteristics of the tumor microenvironment observed in TNCs [28] .
TLR9 levels of expression may have statistical prognostic value. TLR9 overexpression by cancer epithelial [35] [36] [37] [38] [39] [40] [41] . Results from our study are in agreement with those reported in the literature [42] . Indeed, we found an association between TLR9 gene overexpression by tumor epithelial cells and SBR histopathological grade III and hormone receptor negativity. We observed a trend for IBCs with high TLR9 expression to have better MFS after surgery than IBCs with low TLR9 mRNA expression in the total population (P = 0.05), and in various subgroups of poor prognosis including histopathological grade III (P = 0.043) and estrogen receptor negative (P = 0.007). We also observed at the protein level that TNCs with TLR9 overexpression were associated with a better prognosis. Interestingly, TNCs with TLR9 overexpression were significantly correlated with development of a fibrous (P = 1.2×10 −6 ) and inflammatory microenvironment (P < 10 −7 ) with accumulation of CAFs and MICs overexpressing TLR9 and numerous CD4 lymphocytes, Treg lymphocytes and CD8 CD45RO memory cells (P = 0.016). Moreover, high contents of stromal inflammation, CAFs and MICs overexpressing TLR9 and numerous cytotoxic CD8 lymphocytes were also associated with a better prognosis [43] . Cancer-associated chronic inflammation initiated by epithelial cancer cells and stromal/immune cells overexpressing TLR9, is amplified and sustained by a chemokine inducer composed of activated NF-kB and STAT3 [44, 45] which may promote cancer progression and therapeutic resistance [46] . Furthermore, several studies identified TLRs, such as TLR9, as crucial activators of the JAK-STAT3 pathway. Recent data showed that TLR9 is highly expressed in glioblastoma stem-like cells (GSCs) [46] and that activated STAT3 binds to the TLR9 promoter and contributes to TLR9 expression in GSCs [47] , providing a potential mechanism by which infection or inflammation enhances carcinogenesis. In our series of 80 TNCs, we observed that in TNCs with TLR9 overexpression, nuclear phosphoSTAT3 (Tyr705) was identified in 81 % of cancer cells as compared to 31 % of cancer cells in TNCs with normal or low TLR9 level of expression. Conversely, by using phosphoSTAT3 (Ser727), a highly positive nuclear score was observed in 22 % of TNCs with TLR9 overexpression and 67 % of TNCs with normal or low TLR9 expression. PhosphoSTAT3 (Tyr705) and phosphoSTAT3 (Ser727) were also variably expressed by immune and non-immune stromal cells belonging to the tumor microenvironment. We identified a population of CD15+, phosphoSTAT3+ myeloid-derived suppressor cells (MDSCs) with granulocytic morphology that accumulate in peri-vascular and/or within vascular lumen of breast cancer tissues (data not shown). MDSCs are important inhibitors of T-cell responses in solid tumors. It seems that preexisting STAT3 activity in MDSCs, can skew TLR9 signaling toward supporting tumor angiogenesis while blocking antitumor immunity [48] [49] [50] Recently, TLR9 stimulation by CpG-ODN has been shown to activate NF-kB pathway, leading to Th1 immunostimulation and antitumor immune responses [51, 52] . A promising targeted combined therapy should associate T-cell therapy and STAT3 inhibitors linked to CpG/TLR9 that could silence STAT3 in cancer cells and stromal /immune cells and favor down-regulation of cancer stem cells and antitumor immune responses [53, 54] .
In addition, IBCs microenvironment contains tertiary lymphoid structures (TLSs), different subtypes of cancerassociated fibroblasts (CAFs) and dendritic cells (DCs) which are derived from myeloid (MDCs) or lymphoid precursors (plasmacytoid DCs, pDCs). It has been shown that pDCinfiltrating primary breast tumors represent an independent prognostic factor associated with poor outcome [55] . Investigating these subtypes of microenvironment cells will provide important clues in breast carcinogenesis and tumor progression.
In summary, our study contributed to a better biopathological characterization of IBCs subtypes by identifying an activated endosomal TLR9 signaling pathway in 15 % of IBCs, mainly belonging to the TNC subgroup (30-40 %) . Moreover, our results suggest that TLR9 expression is a prognosis biomarker in TNCs, and highlight the interest of initiating clinical trials combining TLR9 agonists and STAT3 inhibitors in TNCs. These results also warrant studies of other altered genes identified in the present study as putative predictive biomarkers for selecting patients most likely to benefit from these drugs [56] .
